Weinan Li

Weinan Li

Auto-generated profile, based on publicly available information

Weinan Li

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Shanghai, China. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
QGQingsong Guo
Qingsong Guo
BGBei Gao
Bei Gao
RSRuiwen Song
Ruiwen Song
WLWeinan Li
Weinan Li
SZShulei Zhu
Shulei Zhu
TYTong Yang
Tong Yang
Delta-like ligand 3 (DLL3) is overexpressed in small cell lung cancer (SCLC) and has been considered an attractive target for SCLC therapy. Rovalpituzumab tesirine was the first DLL3-targeted antibody–drug conjugate (ADC) to enter clinical studies. However, serious adverse events limited progress in the treatment of SCLC with rovalpituzumab tesirine. In this study, we developed a novel DLL3-targeted ADC, FZ-AD005, by using DXd with potent cytotoxicity and a relatively better safety profile to maximize the therapeutic index. FZ-AD005 was generated by a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker to conjugate DXd. Moreover, Fc-silencing technology was introduced in FZ-AD005 to avoid off-target toxicity mediated by FcγRs and showed negligible Fc-mediated effector functions in vitro. In preclinical evaluation, FZ-AD005 exhibited DLL3-specific binding and demonstrated efficient internalization, bystander killing, and excellent in vivo antitumor activities in cell line–derived xenograft and patient-derived xenograft models. FZ-AD005 was stable in circulation with acceptable pharmacokinetic profiles in cynomolgus monkeys. FZ-AD005 was well tolerated in rats and monkeys. The safety profile of FZ-AD005 was favorable, and the highest nonseverely toxic dose was 30 mg/kg in cynomolgus monkeys. In conclusion, FZ-AD005 has the potential to be a superior DLL3-targeted ADC with a wide therapeutic window and is expected to provide clinical benefits for the treatment of patients with SCLC.

17 June 2026
Verified
Other
Open access
QGQingsong Guo
Qingsong Guo
BGBei Gao
Bei Gao
RSRuiwen Song
Ruiwen Song
WLWeinan Li
Weinan Li
SZShulei Zhu
Shulei Zhu
TYTong Yang
Tong Yang
Figure S2 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models




1 October 2024
Verified
Other
Open access
QGQingsong Guo
Qingsong Guo
BGBei Gao
Bei Gao
RSRuiwen Song
Ruiwen Song
WLWeinan Li
Weinan Li
SZShulei Zhu
Shulei Zhu
TYTong Yang
Tong Yang
Figure S5 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models